Company
ImCheck Therapeutics
Exploring uncharted territories in immunomodulation
- Status
- Acquiredas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- France
- imchecktherapeutics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
Funding snapshot
- Latest round
- Grant2024-08-29
Funding rounds
- Grant
- 2024-08-29
About the company
- Status notes
- Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
Products
- Web
- ICT01
Exit
- Acquisition
- 2025-12-15350 million euros and downstream payments contingent upon achievement of regulatory and sales-based milestones, for a total potential consideration up to 1 billion euros
Loading relationship preview